

Emergent BioSolutions Inc.  
 Form 3  
 November 14, 2006

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Kramer Robert (Last) (First) (Middle)		2. Date of Event Requiring Statement (Month/Day/Year) 11/14/2006	3. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [EBS]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) President & CEO EBOL	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
300 PROFESSIONAL DRIVE (Street)						
GAITHERSBURG, MD 20879 (City) (State) (Zip)						

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,065,043 (1)	I	By BioPharm, L.L.C.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title	Amount or Number of		

Edgar Filing: Emergent BioSolutions Inc. - Form 3

				Shares		(I) (Instr. 5)	
Employee Stock Option (right to buy)	06/30/2004	06/30/2007	Class B Common Stock	467,528	\$ 0.1	D	Â
Employee Stock Option (right to buy)	Â (2)	05/25/2010	Class B Common Stock	43,588	\$ 3.5	D	Â
Employee Stock Option (right to buy)	Â (3)	05/25/2010	Class B Common Stock	71,495	\$ 3.5	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kramer Robert 300 PROFESSIONAL DRIVE GAITHERSBURG, MD 20879	Â	Â	Â President & CEO EBOL	Â

## Signatures

/s/Daniel Abdun-Nabi, attorney  
in fact

11/14/2006

\_\_Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- An entity named "RKRAMER, L.L.C." which is wholly owned by Mr. Kramer holds 21.01% (296,875 units) of the equity interest in
- (1) BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 4,065,043 shares of Common Stock. Mr. Kramer disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 854,139 shares.
  - (2) The option is vested with respect to 17,435 shares of Class B Common Stock covered thereby and will vest with respect to the remaining shares as follows: 13,076 shares on December 31, 2006 and 13,077 shares on December 31, 2007.
  - (3) The option is vested with respect to 28,598 shares of Class B Common Stock covered thereby and will vest with respect to the remaining shares as follows: 21,448 shares on December 31, 2006 and 21,449 shares on December 31, 2007.

Â

**Remarks:**  
ExhibitÂ List:

ExhibitÂ 24-PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.